TIANSHAN BIO(SZ:300313)2024-07-03 09:05Revenue Adjustments - The company corrected its 2023 semi-annual report and third-quarter report due to overlapping relationships with suppliers and customers, resulting in a revenue adjustment of CNY 1,034,400 for Q2, CNY 17,342,604 for the first three quarters, and CNY 922,710 for Q4[3][10][12]. - The corrected total operating revenue for the first half of 2023 is CNY 46,322,494.61, down from CNY 47,356,894.61, reflecting a decrease of approximately 2.18%[4]. - The company reported a total operating revenue of CNY 95,556,468.24 for the first three quarters of 2023, down from CNY 112,899,072.24, representing a decline of approximately 15.3%[4]. Cost Adjustments - The total operating costs for the first half of 2023 were adjusted to CNY 58,557,358.46 from CNY 59,591,758.46, indicating a reduction of about 1.74%[4]. - The total operating costs for the first three quarters were adjusted to CNY 107,186,932.20 from CNY 124,529,536.20, reflecting a decrease of about 13.6%[4]. Cash Flow Adjustments - The cash received from sales and services for the first half of 2023 was revised to CNY 42,041,707.30, a decrease of CNY 1,034,400 from the previous figure[4]. - Cash received from sales and services for the first three quarters was revised to CNY 82,672,046.71, a decrease of CNY 17,400,204.00 from the previous amount[4]. Compliance and Apologies - The company emphasized its commitment to improving internal controls and compliance with regulatory requirements to prevent similar issues in the future[13]. - The adjustments do not affect the previously disclosed total profit, net profit, or net profit attributable to shareholders for the 2023 annual report[12]. - The company expressed sincere apologies for any inconvenience caused to investors due to these corrections[6].